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Figure 3
Regenerative indications where child with stored cord blood has
condition
Disease name Family
count
Family count/total
families responding
Autism/apraxia 859 1.99%
Other developmental delay 609 1.41%
Childhood hearing loss 169 0.39%
Cerebral palsy/periventricular
leukomalacia/hypotonia
116 0.27%
Diabetes, type 1 114 0.26%
Inﬂammatory bowel disease 61 0.14%
Hydrocephalus 53 0.12%
Hypoxic-ischemic brain injury 44 0.10%
In-utero brain injury/stroke 38 0.09%
Infant lung disease 30 0.07%
Traumatic brain injury
(post-delivery)
24 0.06%
Muscular dystrophy 15 0.03%
Spinal cord injury 15 0.03%
Diabetes, type II 5 0.01%
Systemic lupus 3 0.01%
TOTAL* 2155 4.98%
*Families may report more than one condition or disease.
Abstracts / Biol Blood Marrow Transplant 20 (2014) S165eS183 S177(“transplant indications”) or 15 diseases or conditions pri-
marily under investigation for autologous stem cell infusion
(“regenerative indications”), regardless of whether they
planned to receive a transplant or infusion.
Results: We received 43,259 completed responses. Of the
families completing the questionnaire, 1.87% reported at
least one transplant indication and 17.04% reported at least
one regenerative indication. Figure 1 shows the total number
and percent of families that reported each of the transplant
and regenerative indications listed. For transplant in-
dications, after subtracting families where the child with the
condition was the family member with stored cells, 1.68% of
families reported at least one indication. The most common
indications reported were Hodgkin’s lymphoma (0.33%),
non-Hodgkin’s lymphoma (0.32%), and acute lymphoblastic
leukemia (0.25%) (Figure 2). Similarly, for regenerative in-
dications, after subtracting families where the child with the
conditionwas not the familymemberwith stored cells, 4.98%
of families reported at least one indication. The most com-
mon indications reported were autism/apraxia (1.99%), other
developmental delay (1.41%), and childhood hearing loss
(0.39%) (Figure 3).
Conclusion: Among families who store newborn stem cells
in private cord blood banks, conditions for which stem cell
transplant or infusion may be indicated or under investiga-
tion are relatively prevalent, especially for regenerative
indications.
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Background: Hematopoietic stem cell transplant (HSCT) is
the only curative option for patients with Diamond-Blackfan
anemia (DBA). However, many patients lack suitable related
or unrelated bone marrow donors. Unrelated cord bloodtransplant (UCBT) has successfully been used to treat many
diseases. Advantages of cord blood include: increased like-
lihood of ﬁnding a suitable graft particularly for racial and
ethnic minorities, rapid availability, lack of risk to the donor,
decreased likelihood of transmitting infections, more
permissive HLA mismatching and decreased incidence of
graft versus host disease (GVHD). Here we describe a cohort
of patients who underwent unrelated umbilical cord blood
transplant (UCBT) for DBA at a single center.
Methods: All patients who underwent UCBT for a diagnosis
of DBA from 1996 to 2011 at Duke University Medical Center
were eligible for this retrospective analysis (n¼6). Patients
were diagnosedwith DBA on the basis of pure red cell aplasia
on bone marrow aspirate and when available by ribosomal
mutation testing (n¼3). Descriptive analysis was used for
measures of engraftment, GVHD and survival.
Results: Patients had a median age of 3.1 years (range: 2.5-
20.3 years), 3 were male and all were caucasian. Prior to
UCBT, patients had a median of 34 (range, 6-230) red cell
transfusions and a median ferritin level of 2213ng/ml (range,
319 e 3328 ng/ml). Five of six patients received busulfan
(1mg/kg/dose x 16), cyclophosphamide (50mg/kg/dose x 4)
and equine Anti-thymocyte globulin (30mg/kg/dose x 3). The
most recent patient received ﬂudarabine (30mg/m2 x 5),
melphalan (70mg/m2 x 2), thiotepa (200mg/m2 x 1), alem-
tuzumab (1mg/kg/dose x 3) and hydroxyurea (30mg/kg/day
x 13). Patients were HLA matched at 4/6 (n¼2), 5/6 (n¼2) or
6/6 (n¼2) using low resolution HLA-A and eB and high
resolution eDRB1 typing. Median total nucleated cell dose
pre-cryopreservation was 9.33x107 cells/kg (range: 2.3-
18.4x107 cells/kg). GVHD prophylaxis was cyclosporine and
steroids. All patients engrafted neutrophils (median 22 days,
range: 19-91 days) and platelets (50K, median 81 days,
range: 41-215 days). Two patients experienced grade II-IV
acute GVHD and one had extensive chronic GVHD. With a
median follow up of 5.5 years (range: 2-14 years), 4 of 6 (67%)
patients are alive and well, full donor chimeras, and free of
transfusions. One patient died at day 70 from veno-occlusive
disease and the second died two years post-transplant from
polyserositis, chronic gut GVHD and kidney failure. None of
the 4 surviving patients suffer from any major chronic
medical problems.
Conclusions: UCBT can successfully be used for the treat-
ment of DBA if otherwise suitable donors are not available.
Survival following UCBT is similar to those reported by
CIBMTR following related and unrelated adult donor trans-
plants for DBA.1
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Hemophagocytic Lymphohistiocytosis (HLH) is a rare im-
munodeﬁciency disease of early childhood characterized by
immune dysregulation due to impaired cytoxic killing and
uncontrolled activation of T cells and macrophages. HLH can
be congenital or acquired; approximately 40 % of children
have an identiﬁed genetic defect. The standard approach to
HLH is several months of therapy with dexamethasone,
cyclosporin and etoposide to achieve disease control, fol-
lowed by allogeneic hematopoietic stem cell transplant
